ACB
Price
$4.54
Change
+$0.07 (+1.57%)
Updated
Jul 3 closing price
Capitalization
238.86M
32 days until earnings call
HCM
Price
$15.81
Change
+$0.12 (+0.76%)
Updated
Jul 3 closing price
Capitalization
2.88B
32 days until earnings call
Interact to see
Advertisement

ACB vs HCM

Header iconACB vs HCM Comparison
Open Charts ACB vs HCMBanner chart's image
Aurora Cannabis
Price$4.54
Change+$0.07 (+1.57%)
Volume$708.07K
Capitalization238.86M
HUTCHMED (China)
Price$15.81
Change+$0.12 (+0.76%)
Volume$59.32K
Capitalization2.88B
ACB vs HCM Comparison Chart in %
Loading...
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACB vs. HCM commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a Hold and HCM is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (ACB: $4.54 vs. HCM: $15.81)
Brand notoriety: ACB: Notable vs. HCM: Not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ACB: 58% vs. HCM: 74%
Market capitalization -- ACB: $238.86M vs. HCM: $2.88B
ACB [@Pharmaceuticals: Other] is valued at $238.86M. HCM’s [@Pharmaceuticals: Other] market capitalization is $2.88B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whileHCM’s FA Score has 1 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • HCM’s FA Score: 1 green, 4 red.
According to our system of comparison, HCM is a better buy in the long-term than ACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 5 TA indicator(s) are bullish while HCM’s TA Score has 5 bullish TA indicator(s).

  • ACB’s TA Score: 5 bullish, 5 bearish.
  • HCM’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both ACB and HCM are a good buy in the short-term.

Price Growth

ACB (@Pharmaceuticals: Other) experienced а +6.57% price change this week, while HCM (@Pharmaceuticals: Other) price change was +3.06% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.02%. For the same industry, the average monthly price growth was +2.94%, and the average quarterly price growth was +92.60%.

Reported Earning Dates

ACB is expected to report earnings on Aug 07, 2025.

HCM is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+2.02% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HCM($2.88B) has a higher market cap than ACB($239M). HCM YTD gains are higher at: 9.715 vs. ACB (6.824). HCM has higher annual earnings (EBITDA): 67.3M vs. ACB (-1.64B). HCM has more cash in the bank: 886M vs. ACB (149M). HCM has less debt than ACB: HCM (86.1M) vs ACB (103M). HCM has higher revenues than ACB: HCM (838M) vs ACB (212M).
ACBHCMACB / HCM
Capitalization239M2.88B8%
EBITDA-1.64B67.3M-2,432%
Gain YTD6.8249.71570%
P/E RatioN/A27.95-
Revenue212M838M25%
Total Cash149M886M17%
Total Debt103M86.1M120%
FUNDAMENTALS RATINGS
ACB vs HCM: Fundamental Ratings
ACB
HCM
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
89
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8960
PRICE GROWTH RATING
1..100
6253
P/E GROWTH RATING
1..100
845
SEASONALITY SCORE
1..100
5095

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACB's Valuation (55) in the Pharmaceuticals Other industry is somewhat better than the same rating for HCM (89) in the Pharmaceuticals Major industry. This means that ACB’s stock grew somewhat faster than HCM’s over the last 12 months.

ACB's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as HCM (100) in the Pharmaceuticals Major industry. This means that ACB’s stock grew similarly to HCM’s over the last 12 months.

HCM's SMR Rating (60) in the Pharmaceuticals Major industry is in the same range as ACB (89) in the Pharmaceuticals Other industry. This means that HCM’s stock grew similarly to ACB’s over the last 12 months.

HCM's Price Growth Rating (53) in the Pharmaceuticals Major industry is in the same range as ACB (62) in the Pharmaceuticals Other industry. This means that HCM’s stock grew similarly to ACB’s over the last 12 months.

HCM's P/E Growth Rating (5) in the Pharmaceuticals Major industry is significantly better than the same rating for ACB (84) in the Pharmaceuticals Other industry. This means that HCM’s stock grew significantly faster than ACB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBHCM
RSI
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
85%
Momentum
ODDS (%)
Bearish Trend 4 days ago
87%
Bullish Trend 4 days ago
75%
MACD
ODDS (%)
Bearish Trend 4 days ago
82%
Bearish Trend 4 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
71%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
89%
Bullish Trend 4 days ago
72%
Advances
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
73%
Declines
ODDS (%)
Bearish Trend 17 days ago
88%
Bearish Trend 7 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
87%
Aroon
ODDS (%)
Bullish Trend 4 days ago
57%
Bullish Trend 4 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
ACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FMDGX36.450.49
+1.36%
Fidelity Mid Cap Growth Index
TWUIX103.231.15
+1.13%
American Century Ultra® I
MCECX13.880.08
+0.58%
Martin Currie Emerging Markets C
GLNLX24.510.10
+0.41%
MFS Global New Discovery R3
TRZPX27.16-0.03
-0.11%
T. Rowe Price European Stock Z

ACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACB has been loosely correlated with CGC. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if ACB jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACB
1D Price
Change %
ACB100%
+1.57%
CGC - ACB
63%
Loosely correlated
+7.56%
OGI - ACB
60%
Loosely correlated
+3.62%
CRON - ACB
56%
Loosely correlated
+2.00%
TLRY - ACB
55%
Loosely correlated
+11.03%
CRDL - ACB
35%
Loosely correlated
+10.79%
More

HCM and

Correlation & Price change

A.I.dvisor tells us that HCM and TLRY have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HCM and TLRY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HCM
1D Price
Change %
HCM100%
+0.76%
TLRY - HCM
27%
Poorly correlated
+11.03%
OGI - HCM
26%
Poorly correlated
+3.62%
CGC - HCM
25%
Poorly correlated
+7.56%
CRDL - HCM
25%
Poorly correlated
+10.79%
ACB - HCM
24%
Poorly correlated
+1.57%
More